Archive · 10 Nov 2025
Novo Nordisk Partners with Emcure for Wider Semaglutide Distribution in India
A Danish company, Novo Nordisk, is teaming up with an Indian company, Emcure Pharmaceuticals, to sell its popular weight-loss medicine, semaglutide.
They will sell it under a new name, Poviztra.
Novo Nordisk wants to make sure many more people in India can get this medicine, even in small towns and villages.
They are partnering with Emcure because Emcure has a large network of sales representatives and pharmacies across the country.
This comes as another big company, Eli Lilly, is also working to sell its weight-loss drug, Tirzepatide, in India with a different partner, Cipla.
The market for weight-loss medicines is getting very busy.
Novo Nordisk is already selling semaglutide in India with other names, but wants to increase its reach.
They promise to price the new medicine competitively.
India has a large number of people who are obese or have diabetes, making it an important market for these drugs.
Novo Nordisk partners with Emcure Pharmaceuticals for exclusive distribution of its weight-loss drug semaglutide in India, launching it as Poviztra.
This partnership aims to expand access to semaglutide across India, including smaller towns and villages, by leveraging Emcure's extensive distribution network.
The move intensifies competition in India's rapidly growing anti-obesity drug market, following Eli Lilly's similar partnership with Cipla for its drug Tirzepatide.
Novo Nordisk currently markets semaglutide in India as Wegovy (injectable) and Rybelsus (oral pill), with Wegovy priced between ₹17,345 to ₹26,015 monthly depending on dosage.
Novo Nordisk seeks to increase its market share in India, where there are over 254 million obese individuals and more than 100 million with diabetes, while facing increased competition from Eli Lilly.
- Who
- Novo Nordisk and Emcure Pharmaceuticals
- What
- Announced an exclusive partnership to distribute Novo Nordisk's weight-loss drug semaglutide under the new brand name Poviztra.
- When
- The announcement was made on Monday. Novo Nordisk currently markets Wegovy (launched June 2025) and Rybelsus (launched 2022) in India. Eli Lilly announced its partnership with Cipla last month.
- Where
- India
- Why
- To increase distribution scale and access for semaglutide in India's growing anti-obesity drug market amidst increasing competition.
Novo Nordisk
Eli Lilly
Weight-Loss Drug Distribution Strategy
Novo Nordisk
Novo Nordisk is partnering with Emcure Pharmaceuticals for exclusive distribution of its weight-loss therapy semaglutide (Poviztra) in India, aiming to increase scale and reach patient pockets beyond their current network.
Eli Lilly
Eli Lilly has partnered with Cipla for distribution of its anti-obesity drug Tirzepatide, indicating a similar strategy of leveraging domestic pharmaceutical companies to expand market reach.
Market Entry and Competition
Novo Nordisk
Novo Nordisk, already marketing semaglutide as Wegovy (injectable) and Rybelsus (oral pill) in India, is expanding its distribution through Emcure to compete in the fast-growing anti-obesity drug market. They previously lost early-mover advantage to Eli Lilly's Mounjaro.
Eli Lilly
Eli Lilly launched Mounjaro (Tirzepatide) in India in March 2025, outperforming Novo Nordisk's sales by 10x as of October 2025. Their new partnership with Cipla aims to further solidify their position.
- Drug 1
- Semaglutide (new brand name: Poviztra)
- Company 1
- Novo Nordisk & Emcure Pharmaceuticals
- Drug 2
- Tirzepatide (Mounjaro)
- Company 2
- Eli Lilly & Cipla
- Novo Nordisk's Existing Semaglutide Brands in India
- Wegovy (injectable, launched June 2025), Rybelsus (oral pill, launched 2022)
- Semaglutide (Wegovy) Pricing (per month)
- 0.25-1mg doses: ₹17,345; 1.7mg: ₹24,280; 2.4mg: ₹26,015
- Target Markets
- India
- Patient Population (India)
- 254 million obese, over 100 million with diabetes
Sources
Novo Nordisk inks collaboration with Emcure, to sell on its weightloss and diabetes drug Wegovy
Zydus, Torrent ready Semaglutide launches in India & Brazil
Novo Nordisk partners Emcure Pharma to commercialise weight loss drug Poviztra in India
Emcure Pharma shares surge 8% after tie up for weight loss drug; details here
Novo Nordisk, Emcure Pharma to launch weight loss drug under new brand in India
